Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Gemcitabine
100%
Single-agent Therapy
100%
Combination Therapy
100%
Response Rate
80%
Phase II Trial
40%
Taxanes
40%
Chemotherapy
20%
New Agents
20%
Malignancy
20%
Paclitaxel
20%
Cisplatin
20%
Docetaxel
20%
Mechanism of Action
20%
Time to Progression
20%
Gemcitabine Plus Cisplatin
20%
Vinca Alkaloids
20%
Chemotherapy-naïve
20%
Maximum Tolerated Dose
20%
Nucleoside Analogues
20%
Camptothecin
20%
Phase I Study
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Chain Termination
20%
Deoxycytidine Kinase
20%
Randomized Phase III Trial
20%
Cytosine Arabinoside
20%
CPT-11
20%
Vinorelbine
20%
Randomized Phase II Trial
20%
Short Infusion
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Gemcitabine
100%
Combination Therapy
100%
Chemotherapy
33%
Cisplatin
33%
Taxane
33%
Docetaxel
16%
Paclitaxel
16%
Phase II Trials
16%
Vinca Alkaloid
16%
Nucleoside Analog
16%
Maximum Tolerated Dose
16%
Camptothecin
16%
Cytarabine
16%
Deoxycytidine Kinase
16%
Vinorelbine
16%
Biochemistry, Genetics and Molecular Biology
Gemcitabine
100%
Cisplatin
33%
Cytosine
16%
Maximum Tolerated Dose
16%
Sanger Sequencing
16%
Phase II Trials
16%
Vinca
16%
Deoxycytidine Kinase
16%
Nucleoside Analogue
16%
Nursing and Health Professions
Camptothecin
16%
Deoxycytidine Kinase
16%